Bcl-2 is a family of evolutionarily related proteins. These proteins govern mitochondrial outer membrane permeabilization (MOMP) and can be either pro-apoptotic (Bax, Bad, Bak and Bok among others) or anti-apoptotic (including Bcl-2 proper, Bcl-xL, and Bcl-w, among an assortment of others). There are a total of 25 genes in the Bcl-2 family known to date. Human genes encoding proteins that belong to this family include: Bak1, Bax, Bal-2, Bok, Mcl-1.
Bcl-2 Family Inhibitors & Modulators

**(+)-Apogossypol**  
(Apogossypol; NSC736630)  
Cat. No.: HY-13408

**Bioactivity:** (+)-Apogossypol (Apogossypol; NSC736630) is a potent inhibitor of Bcl-2 family proteins, competing with the BH3 peptide-binding sites on Bcl-2, Bcl-XL, Mcl-1, Bcl-W, and Bcl-B, but not Bfl-1, with IC50s of 0.5 to 2 μM.

**Purity:** >98%

**Clinical Data:**

**Size:** 5 mg, 10 mg

---

**(-)-Gossypol (acetic acid)**  
((S)-(+)-Gossypol acetic acid)  
Cat. No.: HY-15464D

**Bioactivity:** (S)-Gossypol acetic acid is a inhibitor of Bcl-2, potently induce cell death in Jurkat cells overexpressing Bcl-2 (IC50, 18.1μM) or Bcl-xL (IC50, 22.9μM).

**Purity:** 98.8%

**Clinical Data:**

**Size:** 10mM x 1mL in DMSO, 10 mg, 50 mg

---

**A-1155463**  
(A1155463; A 1155463)  
Cat. No.: HY-19725

**Bioactivity:** A-1155463 is a highly potent and selective BCL-XL inhibitor. A-1155463 shows picomolar binding affinity to BCL-XL (Ki = 0.01 nM), and >1000-fold weaker binding to BCL-2 (Ki = 80 nM) and related proteins BCL-W (Ki = 19 nM) and MCL-1 (Ki > 440 nM).

**Purity:** 98.55%

**Clinical Data:**

**Size:** 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg

---

**A-1210477**  
(A1210477)  
Cat. No.: HY-12468

**Bioactivity:** A-1210477 is an inhibitor of MCL-1 (Ki=0.45 nM in TR-FRET-binding assays), is a much weaker binder of BCL-2 (Ki=0.132 μM) and BCL-XL (Ki=0.660 μM).

**Purity:** 98.89%

**Clinical Data:**

**Size:** 5 mg, 10 mg, 50 mg, 100 mg

---

**A-1331852**  
(A1331852; A 1331852)  
Cat. No.: HY-19741

**Bioactivity:** A-1331852 is an orally available BCL-XL selective inhibitor with a Ki of less than 10 pM.

**Purity:** >98%

**Clinical Data:**

**Size:**

---

**ABT-199**  
(GDC-0199; ABT199; ABT 199; GDC0199; GDC 0199; Venetoclax)  
Cat. No.: HY-15531

**Bioactivity:** ABT-199 is a highly potent, orally bioavailable and Bcl-2-selective inhibitor with Ki of <0.01 nM.

**Purity:** >98.0%

**Clinical Data:**

**Size:** 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

---

**ABT-737**  
(ABT737; ABT 737)  
Cat. No.: HY-50907

**Bioactivity:** ABT-737 is a BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM in cell-free assays, respectively, and shows no inhibition against Mcl-1, Bcl-B or Bfl-1.

**Purity:** 98.04%

**Clinical Data:**

**Size:** 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

---

**AT-101**  
((R)-(-)-Gossypol; R(-)-gossypol acetic acid; AT 101; AT101)  
Cat. No.: HY-15464

**Bioactivity:** AT101, the R(-) enantiomer of Gossypol acetic acid, binds with Bcl-2, Bcl-xL and Mcl-1 with Ki of 0.32 μM, 0.48 μM and 0.18 μM.

**Purity:** >98%

**Clinical Data:**

**Size:** 10 mg, 50 mg

---

**AT-101 (acetic acid)**  
((R)-(-)-Gossypol acetic acid; (-)-Gossypol acetic acid; (R)-Gosyppol acetic acid)  
Cat. No.: HY-15464A

**Bioactivity:** AT101 acetic acid, the R(-) enantiomer of Gossypol acetic acid, binds with Bcl-2, Bcl-xL and Mcl-1 with Ki of 0

**Purity:** 98.48%

**Clinical Data:**

**Size:** 10mM x 1mL in DMSO, 10 mg, 50 mg

---

**BAM7**  
(BAM 7; BAM-7)  
Cat. No.: HY-15361

**Bioactivity:** BAM 7 is a direct and selective activator of proapoptotic Bax with IC50 of 3.3 μM.

**Purity:** 98.47%

**Clinical Data:**

**Size:** 10mM x 1mL in DMSO, 10 mg, 50 mg
Bax inhibitor peptide V5 (Val-Pro-Met-Leu-Lys; BIP-V5; BAX Inhibiting Peptide V5)  
Cat. No.: HY-P0081

Bioactivity: Bax inhibitor peptide V5 is a peptide inhibitor of Bax translocation to mitochondria.

Purity: 99.79%
Clinical Data: Size: 5 mg, 10 mg, 25 mg, 50 mg

BH3I-1 (BH11; BHI-1; BHI 1; BH 3I1)  
Cat. No.: HY-100383

Bioactivity: BH3I-1 is an inhibitor of Bcl-xL with IC50 of 293.95 μM. BH3I-1 is a cell permeable BH3 mimetic that binds to Bcl-xL, BH3I-1 can induce cell death. BH3I-1 is a bak activator.

Purity: >98.0%
Clinical Data: Size: 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg

Gambogic Acid (Beta-Guttiferin)  
Cat. No.: HY-N0087

Bioactivity: Gambogic Acid activates caspases with EC50 of 0

Purity: 99.86%
Clinical Data: Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg

Gossypol (BL 193)  
Cat. No.: HY-13407

Bioactivity: Gossypol has been known to exert a potential for anti-cancer, anti-inflammatory and other important therapeutic activities, gossypol binds and antagonizes anti-apoptotic effect of Bcl-2 family proteins

Purity: >98%
Clinical Data: Size: 100 mg, 200 mg, 500 mg

Gossypol (acetic acid) ((±)-Gossypol-acetic acid)  
Cat. No.: HY-17510

Bioactivity: Gossypol-acetic acid, a polyphenolic compound isolated from cottonseeds, inhibits Bcl-2 by acting as a BH3 mimetic.

Purity: 99.42%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 200 mg, 500 mg

HA14-1 (HA-14-1; HA 14-1)  
Cat. No.: HY-12011

Bioactivity: HA14-1 is a non-peptidic ligand of a Bcl-2 surface pocket with IC50 of ~9 μM.

Purity: >98.0%
Clinical Data: Size: 10mM x 1mL in DMSO, 10 mg, 50 mg

Marinopyrrole A (Maritoclan; (-)-Marinopyrrole A)  
Cat. No.: HY-15613

Bioactivity: Marinopyrrole A is a novel and specific Mcl-1 inhibitor with an IC50 value of 10.1 μM, and shows >8 fold selectivity than BCL-xl (IC50 > 80 μM).

Purity: 99.94%
Clinical Data: Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg

Mcl1-IN-1  
Cat. No.: HY-16669

Bioactivity: Mcl1-IN-1 is a potent Mcl-1-selective inhibitor relative to the related Bcl-2 family protein Bcl-xL; demonstrated good Mcl-1 inhibition (IC50 = 2.4 uM) with no appreciable inhibition of Bcl-xL at 100 uM.

Purity: 98.24%
Clinical Data: Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg

Mcl1-IN-2  
Cat. No.: HY-12826

Bioactivity: Mcl1-IN-2 is a Mcl-1 inhibitor without reported IC50 value.

Purity: >95.0%
Clinical Data: Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg

MIM1 (MIM 1; MIM-1; Inhibitor of Mcl-1)  
Cat. No.: HY-16695

Bioactivity: MIM1 is a selective small molecule inhibitor of Mcl-1(IC50= 4.8 uM) that overcomes Mcl-1-dependent leukemia cell survival.

Purity: >98.0%
Clinical Data: Size: 10mM x 1mL in DMSO, 5 mg, 10 mg
Navitoclax (ABT-263; ABT 263; ABT263)  
Cat. No.: HY-10087

**Bioactivity:** Navitoclax is a potent and orally bioavailable Bcl-2 family protein inhibitor that binds with high affinity ($K_I < 1 \text{nM}$) to multiple anti-apoptotic Bcl-2 family proteins including Bcl-x$_L$, Bcl-2 and Bcl-w.

**Purity:** 99.34%

**Clinical Data:**

Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 25 mg, 50 mg, 100 mg

---

Obatoclax (Obatoclax Mesylate; GX15-070)  
Cat. No.: HY-10969

**Bioactivity:** Obatoclax (GX15-070) is Bcl-2 homology domain-3 (BH3) mimetic, antagonize all antiapoptotic Bcl-2 family proteins (average IC50, 3 umol/L), including Mcl-1 (IC50, 2

**Purity:** 99.06%

**Clinical Data:**

Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg

---

Pyridoclax (MR-29072)  
Cat. No.: HY-12527

**Bioactivity:** Pyridoclax(MR-29072) is a potent Mcl-1 inhibitor with Kd value of 25 nM.

**Purity:** 99.73%

**Clinical Data:**

Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg

---

UMI-77  
Cat. No.: HY-18628

**Bioactivity:** UMI-77 is a novel selective Mcl-1 SMI inhibitor. UMI-77 binds to the BH3 binding groove of Mcl-1 with Ki of 490 nM, showing selectivity over other members of anti-apoptotic Bcl-2 members.

**Purity:** 98.67%

**Clinical Data:**

Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg

---

WEHI-539 (WEHI539; WEHI 539)  
Cat. No.: HY-15607

**Bioactivity:** WEHI-539 is a selective inhibitor of Bcl-X$_L$ with IC$_{50}$ of 1.1 nM.

**Purity:** >98%

**Clinical Data:**

Size: 5 mg, 10 mg, 50 mg, 100 mg

---

WEHI-539 (hydrochloride) (WEHI539 hydrochloride; WEHI 539 hydrochloride)  
Cat. No.: HY-15607A

**Bioactivity:** WEHI-539 hydrochloride is a selective inhibitor of Bcl-X$_L$ with IC$_{50}$ of 1.1 nM.

**Purity:** 97.85%

**Clinical Data:**

Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg